BC Extra | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

CymaBay lost three quarters of its market value Monday after atypical histological findings prompted it to hold its lead program and discontinue two more trials, all developing seladelpar for liver indications. The $4.22 (76%) decline...
BC Innovations | Sep 14, 2017
Strategy

Numerate’s Intelligence

With three new partnerships formed since June, Numerate Inc. is picking up steam and demonstrating that industry and academic groups alike are finding utility in its AI platform, which can build robust predictive models for...
BC Innovations | Nov 15, 2016
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Cell culture and mouse studies identified a non-acidic sulfonamide-based GPR120 agonist that could help treat insulin resistance in obesity. Chemical synthesis and testing of non-acidic sulfonamide analogs in cell-based GPR120 ligand-binding assays yielded...
BC Innovations | Nov 6, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes G protein-coupled receptor 120 (GPR120; O3FAR1) Mouse and human sample studies suggest a class of fatty acids could help treat diabetes. In subcutaneous...
BC Innovations | Nov 6, 2014
Targets & Mechanisms

Greasing insulin

An entirely new class of fatty acids has just been discovered that potentially is more potent than the w-3 fatty acids found in fish oil. The new fatty acids-which work through G protein-coupled receptor 120,...
BC Innovations | Aug 14, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes G protein-coupled receptor 120 (GPR120; O3FAR1) Cell culture and mouse studies have identified a GPR120 agonist that could be used to treat type...
BioCentury | Aug 12, 2013
Emerging Company Profile

Sensor: Combination gut shot

Sensor Pharmaceuticals Inc. is using its Synitivity technology to modify and restrict small molecules to the gut, thereby preventing systemic absorption and reducing potential toxicity. The company expects the improved safety will allow it to...
BC Innovations | Mar 8, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity G protein-coupled receptor 120 (O3FAR1; GPR120) Mouse and genetic studies suggest defects in GPR120 signaling increase susceptibility to obesity and obesity-related pathologies. GPR120-deficient...
BC Innovations | Mar 8, 2012
Distillery Therapeutics

Indication: Autoimmune Disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Indoleamine 2, 3-dioxygenase (INDO; IDO) Mouse studies suggest IDO could help treat and prevent autoimmune diseases. In lupus-prone mice, an IDO inhibitor...
BC Innovations | Mar 8, 2012
Targets & Mechanisms

An obesity angle for GPR120

An international team of researchers has shown that dysfunction of the fatty acid receptor GPR120 leads to obesity and obesity-associated metabolic disorders such as glucose intolerance and fatty liver. 1 The findings come less than...
Items per page:
1 - 10 of 12